PLOS Pathogens

Icahn School of Medicine at Mount Sinai Names New Chair of Microbiology

Retrieved on: 
Tuesday, April 11, 2023
Infection, DENV, DNA, Human, Vaccination, University, HIV, Icahn School of Medicine at Mount Sinai, SARS-CoV-2, Teaching, COVID-19, PLOS Pathogens, Postgraduate education, American Academy, Biomedical sciences, Research, Mount Sinai, Mentorship, Immunology, RNA, Doctor of Philosophy, National Institutes of Health, Bangladesh Technical Education Board, Student, Pontifical University of Salamanca, Journal, Maharashtra Institute of Medical Education and Research, Publication, Vaccine, MD, Fever Dream, Orthornavirae, Tufts University Graduate School of Biomedical Sciences, Division, Immune system, Escape Room, Viral, Faculty, NIAID, Mount Sinai Health System, Virus, NIH, Medical education, Management, Nursing, Microbiology, Virology

NEW YORK, April 11, 2023 /PRNewswire-PRWeb/ -- Ana Fernandez-Sesma, PhD, has been appointed Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai. Dr. Fernandez-Sesma will direct all educational and research functions of the Department, while cultivating an academic culture that advances insights into virology, vaccinology, immunology, and microbiology, and encourages innovative approaches to teaching and mentoring.

Key Points: 
  • Ana Fernandez-Sesma, PhD, a distinguished investigator, brings leadership experience in virology, vaccinology, immunology, and microbiology
    NEW YORK, April 11, 2023 /PRNewswire-PRWeb/ -- Ana Fernandez-Sesma, PhD, has been appointed Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai.
  • "I am honored that she brings her immense experience and passion as we continue the advancement of innovative approaches in microbiology and virology at Icahn Mount Sinai."
  • Dr. Fernandez-Sesma is an alumna of Icahn Mount Sinai, having earned her PhD in Biomedical Sciences and MS in Biomedical Sciences from the Graduate School of Biomedical Sciences.
  • She is highly dedicated to graduate education and mentoring, and co-directed the Microbiology Main Training Area of the Graduate School of Biomedical Sciences at Icahn Mount Sinai from 2010 to 2020.

Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

Retrieved on: 
Tuesday, August 16, 2022
Association, Multimedia, International Association of Research Institutes in the History of Art, Molecular biophysics, Section, Valganciclovir, Porcine circovirus associated disease, Gene expression, American Cancer Society, Cancer, International Symposium on Endovascular Therapy, Yale School of Medicine, PLOS Pathogens, Research, Knowledge, Epstein–Barr virus, Department, Director, Infection, DNA, Therapy, Cell proliferation, Prognosis, Journal, SAN, Associate, Society, Drug development, Cytokine, Virus, International Association, National Cancer Institute, Publication, EBV, Yale University, Nasdaq, Biochemistry, National, Organization, Vaccine, Pharmaceutical industry, Microbiology, Pathology, Virology

SAN DIEGO, Aug. 16, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Association for Research on Epstein-Barr Virus and Associated Disease (EBV Association) has elected Viracta's Chief Scientific Officer, Ayman Elguindy, Ph.D., to its Governing Board.

Key Points: 
  • SAN DIEGO, Aug. 16, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Association for Research on Epstein-Barr Virus and Associated Disease (EBV Association) has elected Viracta's Chief Scientific Officer, Ayman Elguindy, Ph.D., to its Governing Board.
  • The International Association for Research on Epstein-Barr Virus and Associated Diseases is a 35-year-old non-profit organization.
  • The association organizes the International Symposium on EBV research; a convention that encourages cooperative activities between institutions, organizations and societies that have interests in common relating to basic and applied research on EBV and associated diseases.
  • I look forward to contributing to further advancements in the understanding of EBV, and the treatment of EBV-associated diseases."

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”

Retrieved on: 
Tuesday, April 12, 2022
CEO, XV, Clinical trial, Northwestern Health Sciences University, HIV, U.S. Securities and Exchange Commission, Security (finance), Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SHIV, Food, Compliance, GLOBE, CCR5, Patient, Immunoglobulin G, 100,000, Form 10-K, Simian immunodeficiency virus, Infection, PLOS Pathogens, Oregon Health & Science University, Company, OTCQB, Vaccine, Social conditions in Honduras, Forward-looking statement, Optimism, Mab, Partnership, FDA, Cancer, Pharmaceutical industry, Leronlimab

The study followed five HIV+ human participants who, after successfully transitioning to once weekly subcutaneous leronlimab, halted their previous daily oral antiretroviral therapy regimens.

Key Points: 
  • The study followed five HIV+ human participants who, after successfully transitioning to once weekly subcutaneous leronlimab, halted their previous daily oral antiretroviral therapy regimens.
  • These five participants came from an extension study, consisting of patients who were virologically suppressed in a prior study of leronlimab.
  • All five long-term participants successfully maintained HIV suppression via leronlimab monotherapy for over seven years, with no evidence of viral escape.
  • To monitor the anatomical penetrance of leronlimab, rhesus macaques acutely infected with simian human immunodeficiency virus (SHIV) were treated with high intravenous doses of leronlimab for 12 weeks.